文献速递炎症性肠病

炎症性肠病生物制剂临床试验纳入的患者不能代表真实世界人群

Patients Included in Clinical Trials of Biological Drugs for Inflammatory Bowel Disease Do Not Represent the Real-World Population.
PubMed 文献 · Am J Gastroenterol · 2025-07-30

这项在西班牙萨拉戈萨Miguel Servet大学医院开展的回顾性观察研究纳入2017年1月至2022年12月期间开始生物制剂治疗的连续炎症性肠病患者,按阿达木单抗、英夫利西单抗、戈利木单抗、乌司奴单抗或维得利珠单抗关键随机临床试验标准评估合格性。631例次治疗中仅16.9%符合关键随机临床试验标准、8%符合较新随机临床试验标准,合格与不合格患者在疗效、安全性和治疗持续性方面无显著差异。

要点

  • 仅16.9%的真实世界患者符合关键随机临床试验标准,8%符合较新随机临床试验标准。
  • 疾病相关标准是最常未满足的标准,占57.3%。
  • 合格与不合格患者在应答率、缓解率、不良事件及停药方面无显著差异。

核心结论

  • 仅少数真实世界炎症性肠病患者符合相应随机临床试验标准,对这类试验的外部效度提出质疑。
  • 真实世界使用生物制剂时,合格与不合格患者的有效性和安全性相似,凸显实用临床判断在治疗决策中的重要性。

研究设计与样本

  • 西班牙萨拉戈萨Miguel Servet大学医院的回顾性观察研究。
  • 纳入2017年1月至2022年12月期间开始生物制剂治疗的连续克罗恩病或溃疡性结肠炎患者。
  • 按阿达木单抗、英夫利西单抗、戈利木单抗、乌司奴单抗或维得利珠单抗关键随机临床试验标准评估合格性。
  • 在14-16周和54周评估临床有效性和安全性,采用生存分析评估治疗持续性。

主要发现

  • 477例患者共启动631例次生物制剂治疗。
  • 仅16.9%符合关键随机临床试验标准,8%符合较新随机临床试验标准。
  • 疾病相关标准是最常未满足的标准,占57.3%。
  • 溃疡性结肠炎患者较克罗恩病患者更不易符合标准(23% vs 4%,P < 0.001)。
  • 合格与不合格患者在应答率、缓解率、不良事件或停药方面无显著差异。

临床怎么用

  • 作者认为,真实世界生物制剂治疗中合格与不合格患者的有效性和安全性相似,凸显实用临床判断在治疗决策中的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Clinical trials are the key to research in inflammatory bowel disease therapeutics. However, their external validity has been poorly evaluated, as have the outcomes in patients who do not meet the inclusion criteria. METHODS: This retrospective observational study at Miguel Servet University Hospital, Zaragoza, Spain, included all consecutive patients diagnosed with Crohn's disease or ulcerative colitis who initiated biologic treatments between January 2017 and December 2022. Eligibility was assessed against the criteria of pivotal randomized clinical trials (RCTs) for adalimumab, infliximab, golimumab, ustekinumab, or vedolizumab. Clinical effectiveness and safety were evaluated at 14-16 weeks and 54 weeks, with treatment persistence assessed using survival analysis. Effectiveness and persistence were assessed to analyze whether patient selection has an impact on different clinical outcomes. RESULTS: A total of 631 biologic treatments were initiated in 477 patients. Only 16.9% met the RCT criteria according to pivotal RCTs and 8% with newer RCTs. Disease-related criteria were the most frequently unmet (57.3%). Patients with ulcerative colitis were less likely to meet the criteria compared with patients with Crohn's disease (23% vs 4%, P < 0.001). No significant differences were observed in response rates, remission rates, adverse events, or drug discontinuation between eligible and noneligible patients. Survival analysis showed no differences in treatment persistence between both groups (hazard ratio 1.01, 95% confidence interval 0.73-1.38). DISCUSSION: Only a minority of real-world patients with inflammatory bowel disease would qualify for corresponding RCTs, questioning the external validity of these trials. However, real-world use of biologics demonstrated similar effectiveness and safety in eligible and noneligible patients, underscoring the importance of practical clinical judgement in therapeutic decisions.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Casas Deza D, Larrubia Domínguez C, Pascual Oliver A, et al. Patients Included in Clinical Trials of Biological Drugs for Inflammatory Bowel Disease Do Not Represent the Real-World Population. Am J Gastroenterol. 2025. PMID: 40736698. doi:10.14309/ajg.0000000000003670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。